Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate NervGen Pharma Corp. before investing.

In this article, we go over a few key elements for understanding NervGen Pharma Corp.’s stock price such as:

• NervGen Pharma Corp.’s current stock price and volume
• Why NervGen Pharma Corp.’s stock price changed recently
• Upgrades and downgrades for NGEN from analysts
• NGEN’s stock price momentum as measured by its relative strength

About NervGen Pharma Corp. (NGEN)

Before we jump into NervGen Pharma Corp.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Want to learn more about NervGen Pharma Corp.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about NervGen Pharma Corp..

NervGen Pharma Corp.’s Stock Price as of Market Close

As of August 10, 2026, 4:00 PM, CST, NervGen Pharma Corp.’s stock price was $1.700.

NervGen Pharma Corp. is down 0.58% from its previous closing price of $1.710.

During the last market session, NervGen Pharma Corp.’s stock traded between $1.695 and $1.740. Currently, there are approximately 57.24 million shares outstanding for NervGen Pharma Corp..

NervGen Pharma Corp.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

NervGen Pharma Corp. Stock Price History

NervGen Pharma Corp.’s (NGEN) price is currently up 4.94% so far this month.

During the month of August, NervGen Pharma Corp.’s stock price has reached a high of $1.760 and a low of $1.605.

Over the last year, NervGen Pharma Corp. has hit prices as high as $6.300 and as low as $1.580. Year to date, NervGen Pharma Corp.’s stock is up 849900%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused NervGen Pharma Corp. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of August 07, 2026,, no analysts have changed their rating of NervGen Pharma Corp.’s stock over the last month.

Additionally, you'll want to evaluate NervGen Pharma Corp.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on NervGen Pharma Corp.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about NervGen Pharma Corp. (NGEN) by visiting AAII Stock Evaluator.

Relative Price Strength of NervGen Pharma Corp.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 07, 2026, NervGen Pharma Corp. has a weighted four-quarter relative price strength of -12.30%, which translates to a Momentum Score of 20 and is considered to be Very Weak.

Want to learn more about how NervGen Pharma Corp. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

NervGen Pharma Corp. Stock Price: Bottom Line

As of August 10, 2026, NervGen Pharma Corp.’s stock price is $1.700, which is down 0.58% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like NervGen Pharma Corp. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.